CN1263439A - 用于处于紧张状态的患者的营养组合物 - Google Patents
用于处于紧张状态的患者的营养组合物 Download PDFInfo
- Publication number
- CN1263439A CN1263439A CN98807193A CN98807193A CN1263439A CN 1263439 A CN1263439 A CN 1263439A CN 98807193 A CN98807193 A CN 98807193A CN 98807193 A CN98807193 A CN 98807193A CN 1263439 A CN1263439 A CN 1263439A
- Authority
- CN
- China
- Prior art keywords
- composition
- carnitine
- alkanoyl
- anxiety
- genseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 235000016709 nutrition Nutrition 0.000 title abstract 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims abstract description 12
- 240000003444 Paullinia cupana Species 0.000 claims abstract description 12
- 235000000556 Paullinia cupana Nutrition 0.000 claims abstract description 12
- -1 alkanoyl L-carnitine Chemical compound 0.000 claims abstract description 11
- 239000001630 malic acid Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims abstract description 7
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 7
- 235000011090 malic acid Nutrition 0.000 claims abstract description 7
- 239000000419 plant extract Substances 0.000 claims abstract 3
- 240000000143 Turnera diffusa Species 0.000 claims description 10
- 235000004952 turnera diffusa Nutrition 0.000 claims description 10
- 208000019901 Anxiety disease Diseases 0.000 claims description 9
- 230000036506 anxiety Effects 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 6
- 229940083466 soybean lecithin Drugs 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 241000208343 Panax Species 0.000 claims description 2
- 235000002791 Panax Nutrition 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000005515 coenzyme Substances 0.000 claims description 2
- IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 206010052005 Psychogenic erectile dysfunction Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229940042126 oral powder Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 1
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 abstract 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 abstract 1
- 229940067606 lecithin Drugs 0.000 abstract 1
- 235000010445 lecithin Nutrition 0.000 abstract 1
- 239000000787 lecithin Substances 0.000 abstract 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 abstract 1
- 229960000317 yohimbine Drugs 0.000 abstract 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 5
- 230000000378 dietary effect Effects 0.000 description 5
- 230000001256 tonic effect Effects 0.000 description 5
- 240000004371 Panax ginseng Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 230000035946 sexual desire Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 108010011485 Aspartame Proteins 0.000 description 3
- 241000675108 Citrus tangerina Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical class OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000682653 Corynanthe Species 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 235000008690 Pausinystalia yohimbe Nutrition 0.000 description 1
- 235000009206 Turnera diffusa Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001805 chlorine compounds Chemical group 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM97A000435 | 1997-07-16 | ||
| IT97RM000435A IT1293539B1 (it) | 1997-07-16 | 1997-07-16 | Composizione nutritiva per soggetti in stato di debilitazione causato da stress |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1263439A true CN1263439A (zh) | 2000-08-16 |
Family
ID=11405180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98807193A Pending CN1263439A (zh) | 1997-07-16 | 1998-07-10 | 用于处于紧张状态的患者的营养组合物 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0999757A1 (ko) |
| JP (1) | JP2001510026A (ko) |
| KR (1) | KR20010021694A (ko) |
| CN (1) | CN1263439A (ko) |
| AU (1) | AU727448B2 (ko) |
| CA (1) | CA2296540A1 (ko) |
| HU (1) | HUP0004526A3 (ko) |
| IT (1) | IT1293539B1 (ko) |
| PL (1) | PL338079A1 (ko) |
| SK (1) | SK181999A3 (ko) |
| WO (1) | WO1999003364A1 (ko) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100411655C (zh) * | 2002-09-28 | 2008-08-20 | 法马顿股份有限公司 | 含有人参和亚马逊香无患子提取物的组合物 |
| CN113116898A (zh) * | 2021-04-20 | 2021-07-16 | 北京天玺宝科技有限公司 | 一种具有减肥功能的包含左卡尼汀或乙酰左卡尼汀和育亨宾的组合物及其应用 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT410277B (de) * | 2001-02-22 | 2003-03-25 | Peter Dr Frigo | Getränk |
| LV12978B (en) * | 2001-09-07 | 2003-05-20 | Ivars Kalvins | Pharmaceutical composition |
| ITRM20010708A1 (it) * | 2001-12-04 | 2003-06-04 | Sigma Tau Ind Farmaceuti | Uso di una alcanoil l-carnitina per il trattamento della disfunzione erettile. |
| DE102005053241A1 (de) * | 2005-11-08 | 2007-05-16 | Schwabe Willmar Gmbh & Co | Extrakte aus der Rinde von Corynanthe-Arten und deren Verwendung sowie diese Extrakte enthaltende Arzneimittel, diätetische Lebensmittel und pharmazeutische Zubereitungen |
| US20100255127A1 (en) * | 2007-11-21 | 2010-10-07 | Kracie Pharma, Ltd. | Aromatase inhibitor |
| JP6446265B2 (ja) * | 2014-12-26 | 2018-12-26 | 花王株式会社 | 固形状組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5626849A (en) * | 1995-06-07 | 1997-05-06 | Reliv International, Inc. | Weight loss composition for burning and reducing synthesis of fats |
| FR2748659B1 (fr) * | 1996-05-14 | 1998-07-24 | Lvmh Rech | Composition topique amincissante |
| US5744187A (en) * | 1996-12-16 | 1998-04-28 | Gaynor; Mitchel L. | Nutritional powder composition |
-
1997
- 1997-07-16 IT IT97RM000435A patent/IT1293539B1/it active IP Right Grant
-
1998
- 1998-07-10 WO PCT/IB1998/001056 patent/WO1999003364A1/en not_active Application Discontinuation
- 1998-07-10 CN CN98807193A patent/CN1263439A/zh active Pending
- 1998-07-10 HU HU0004526A patent/HUP0004526A3/hu unknown
- 1998-07-10 KR KR1020007000253A patent/KR20010021694A/ko not_active Application Discontinuation
- 1998-07-10 AU AU79277/98A patent/AU727448B2/en not_active Ceased
- 1998-07-10 PL PL98338079A patent/PL338079A1/xx unknown
- 1998-07-10 JP JP2000502680A patent/JP2001510026A/ja active Pending
- 1998-07-10 SK SK1819-99A patent/SK181999A3/sk unknown
- 1998-07-10 CA CA002296540A patent/CA2296540A1/en not_active Abandoned
- 1998-07-10 EP EP98929576A patent/EP0999757A1/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100411655C (zh) * | 2002-09-28 | 2008-08-20 | 法马顿股份有限公司 | 含有人参和亚马逊香无患子提取物的组合物 |
| CN113116898A (zh) * | 2021-04-20 | 2021-07-16 | 北京天玺宝科技有限公司 | 一种具有减肥功能的包含左卡尼汀或乙酰左卡尼汀和育亨宾的组合物及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999003364A1 (en) | 1999-01-28 |
| PL338079A1 (en) | 2000-09-25 |
| AU7927798A (en) | 1999-02-10 |
| SK181999A3 (en) | 2000-10-09 |
| CA2296540A1 (en) | 1999-01-28 |
| HUP0004526A2 (hu) | 2001-04-28 |
| ITRM970435A0 (ko) | 1997-07-16 |
| EP0999757A1 (en) | 2000-05-17 |
| JP2001510026A (ja) | 2001-07-31 |
| KR20010021694A (ko) | 2001-03-15 |
| ITRM970435A1 (it) | 1999-01-16 |
| IT1293539B1 (it) | 1999-03-01 |
| AU727448B2 (en) | 2000-12-14 |
| HUP0004526A3 (en) | 2001-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101248873A (zh) | 具有视力保护功能的饮用食品 | |
| CN102640926A (zh) | 一种调节睡眠的食疗产品及其制备方法 | |
| CN102160664A (zh) | 儿童营养饮料 | |
| DE60214849T2 (de) | Chromium/biotin behandlung von dyslipidämie | |
| CN1263439A (zh) | 用于处于紧张状态的患者的营养组合物 | |
| CN101396115B (zh) | 一种低聚木糖健胃润肠口服液及其制备方法 | |
| US5482712A (en) | Galenic composition | |
| US20060269623A1 (en) | Herbal composition and method of use for promoting erections and treating erectile dysfunction in men | |
| CN103763944A (zh) | 饮食性多组分系统 | |
| RU2197868C2 (ru) | Биологически активная пищевая добавка (варианты) | |
| AT412381B (de) | Kombinations-präparat, enthaltend mineralstoffe, vitamine, kohlenhydrate und aminosäuren | |
| RU2316973C1 (ru) | Кофе для похудения | |
| WO2006007818A2 (de) | Verfahren zur systemischen biokorrektur eines organismus | |
| EP2548564B1 (de) | Pharmazeutisches Mittel, Ernährung für einen Patienten sowie Verfahren zur Gewichtsreduzierung | |
| CN103028094A (zh) | 一种治疗冠心病的中成药 | |
| KR20090024215A (ko) | 인간의 성적 활동성을 향상시키기 위한 수단과 방법들 | |
| CN1524455A (zh) | 一种女贞子功能性饮料制剂及其制备方法 | |
| EP4297588A1 (de) | Pulverförmiges nahrungsergänzungsmittel zur herstellung eines getränks | |
| EP2796143A1 (de) | Pharmazeutisches homöopathisches Arzneimittel zur Gewichtsreduktion | |
| CN1150932C (zh) | 一种治疗心血管系统疾病的静脉注射液制备方法 | |
| Sawant et al. | National Journal of Research in Ayurved Science | |
| Mossman | Dietary supplements for diabetes | |
| DE20204843U1 (de) | Mikronährstoffkombinationsprodukt, geeignet für die nutritive Ergänzung bei einem erhöhten Bedarf an Mikronährstoffen, insbesondere bei Patienten mit Diabetes und/oder Herz-Kreislauf-Erkrankungen | |
| D'Huyvetter | Complementary and alternative medicine in diabetes | |
| Umoh et al. | Determination Of Nutritional Potential Of Cymbopogon Citratus (DC) Staph By Atomic Absorption Spectroscopy And Its Health Benefits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |